Evidence map›Paper›PMID 41968987›Full record

ArticleCancer biology & medicine2026

Integrative multi-omic analysis identified

Yaxin Zhao, Han Wang, Ying Wang, Yizhou Jiang, Xin Hu, Zhiming Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yaxin ZhaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Han WangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ying WangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yizhou JiangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xin Hu *Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-8160-8362
Zhiming Shao *Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-4503-148X

Funding

Ministry of Science and Technology of China 2023YFC3402504Ministry of Science and Technology of China 2023YFF0613304Ministry of Science and Technology of China 2023YFF1205003National Key R&D Program of China 2023YFF0613300National Key R&D Program of China 2023YFF1205003National Natural Science Foundation of China 82272957National Natural Science Foundation of China 82303735National Natural Science Foundation of China 82473499
6 · The paper itself

Abstract

objectiveThe luminal androgen receptor (LAR) subtype of triple-negative breast cancer (TNBC) differentiation displays low proliferation yet strong metastatic potential and a poor chemotherapy response. This study aimed to define the molecular basis of the LAR subtype and identify actionable therapeutic targets.

methodsComprehensive multi-omic analyses were performed on the FUSCC-TNBC cohort, integrating whole-exome sequencing, RNA sequencing, and functional validation

resultsThe LAR subtype was enriched for

conclusionsThe LAR subtype harbors two therapeutic vulnerabilities:

Indexed as

Erb-b2 Receptor Tyrosine KinasesMutationTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCellular SenescenceFemaleHumansMiceMultiomicsReceptors, AndrogenERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Androgencellular senescenceimmunotherapy resistanceluminal androgen receptor subtypeTriple-negative breast cancer

Identifiers

PMID41968987
PMCPMC13059881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.